Module home
Module introduction
Pre-module test
Module information
About the author
Section 1: Dietary and
pharmacological weight control
(1.1) Section 1: Dietary and pharmacological weight control
(1.2) Getting started
(1.3) Factors to consider
(1.4) A high price to pay?
(1.5) Mechanisms of weight gain
(1.6) The metabolic syndrome
(1.7) The metabolic syndrome
(1.8) Metabolic syndrome and antipsychotics
(1.9) For debate
(1.10) Interventions against weight loss – the evidence
(1.11) Diets people may try …
(1.12) Comparison of four diets: weight loss at 28 weeks
(1.13) Activity: Foods according to their glycaemic index
(1.14) Foods according to their glycaemic index
(1.15) Reflection
(1.16) Pharmacological interventions for weight gain
(1.17) Licensed slimming drugs: limitations
(1.18) Slimming drugs recently withdrawn, suspended or
recommended for suspension by the European Medicines Agency
(1.19) In the pipeline
(1.20) Section 1: Recap
(1.21) Test your memory! (optional)
(1.22) Section
1: Summary
Section 2: Physical
activity
(2.1) Section 2: Physical activity
(2.2) Benefits and associated risks of regular physical
activity
(2.3) The evidence according to Cochrane
(2.4) Pre-exercise health screening:
cardiovascular risk
(2.5) QT prolongation and Torsades de pointes: the Arizona-CERT
list
(2.6) Examples of drugs associated with QT prolongation
(2.7) Physical activity and drugs of abuse
(2.8) Venous thromboembolism
(2.9) How to choose exercise
(2.10) Aerobic and anaerobic exercise
(2.11) Looking good...
(2.12) Activity: Calorie counter
(2.13) Calorie counter
(2.14) Principles for prescribing exercise
(2.15) Special considerations in patients with
mental health problems
(2.16) Final word
(2.17) Section 2: Recap
(2.18) Section 2:
Summary
Section 3:
Smoking
(3.1) Section 3: Smoking
(3.2) Getting started
(3.3) Getting started
(3.4) Smoking and mental illness
(3.5) The epidemiology of smoking in mental
illness
(3.6) Why do patients with severe mental
illness smoke more?
(3.7) Is smoking related to antipsychotic
use?
(3.8) Interventions for smoking cessation –
non-pharmacological approaches
(3.9) What about smoking bans?
(3.10) Interventions for smoking cessation
– pharmacological approaches
(3.11) Available evidence for patients
with severe mental illness
(3.12) How do bupropion and varenicline
work?
(3.13) Undesirable side effects
(3.14) Outlook: Can meta-analyses of effectiveness studies ever
reliably assess safety issues?
(3.15) Undesirable side effects
(3.16) What is snus?
(3.17) Section 3: Recap
(3.18) Section
3: Summary
Module
summary
Module test
References
Further reading
Take-home notes
Send feedback
Annual revisions
Annual revisions
|